5 Top Weekly NASDAQ Biotech Stocks: vTv Increases 163 Percent
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Your trusted source for investing success
Your trusted source for investing success
vTv Therapeutics, Teligent, EyePoint Pharmaceuticals, Catalyst Biosciences and Eleven Biotherapeutics were last week’s top gainers.
Novelion Therapeutics, EyePoint Pharmaceuticals, CytRx, Viking Therapeutics and AVEO Pharmaceuticals were last week’s top gainers.
These companies are engaged in a wide range of compelling research around everything from respiratory devices and inflatable tissue to disappearing stents.
Cardiome, Avid, XBiotech, Fennec and Compugen were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
Second Sight, Juniper, Athersys, Aptose and ArQule were last week’s five top-gaining NASDAQ biotech stocks. See what moved their share prices.
Through their multiple holdings, ETFs provide immediate diversification to buyers. That’s particularly important in the medical device market.
By Jocelyn Aspa
Shares of 3D Systems have increased more than 30 percent since releasing its Q4 and full year 2017 earnings on February 28.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to it’s year-to-date (YTD) increase. YTD the NBI increased 4.3 percent as of 1:00 p.m. EST Friday.
Catalyst Biosciences, Adverum Biotechnologies, MannKind, Galectin Therapeutics and Aptose Biosciences topped last week’s NASDAQ biotech stock list.
Catalyst Biosciences, Adverum Biotechnologies, MannKind, Galectin Therapeutics and Aptose Biosciences topped last week’s NASDAQ biotech stock list.
A market currently estimated to be worth $389 billion worldwide medical devices enjoyed a positive developing year in 2017. However, the issue of taxes is still present and played a role in the expectations for the market moving forward.
The medical device industry is concentrated in the US, which holds a 45 percent share of the market. But keep an eye on emerging markets too.
By Amanda Kay
The medical devices sector is currently worth $389 billion. What were the top medical device news this year? INN compiled a list of the top headlines.
Viking Therapeutics, Second Sight Medical Products, Ekso Bionics Holdings, Ohr Pharmaceutical and Cardiome Pharma topped last week’s NASDAQ biotech stock list.
We examine how the FDA classifies, regulates and approves medical devices.
CASI Pharmaceuticals, Neptune Tech & Bioresource, Vermilion, Trillium Therapeutics and Xoma topped last week’s NASDAQ biotech stock list.
Collegium Pharmaceutical, Depomed, Xoma, ChromaDex and Ophthotech topped last week’s NASDAQ biotech stock list.
Sierra Oncology, Iradimed, Accuray, Novan and KalVista Pharmaceutical topped last week’s NASDAQ biotech stock list.
In order to keep a closer look on the effectiveness of cardiovascular devices, the US Food and Drug Administration is introducing new guidelines for the promotion of medical device innovation.
